Immuneering (IMRX)
(Real Time Quote from BATS)
$3.50 USD
+0.07 (2.04%)
Updated Aug 5, 2025 02:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IMRX 3.50 +0.07(2.04%)
Will IMRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IMRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMRX
IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug
IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study
IMRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for IMRX
Immuneering (IMRX) Jumps After Securing U.S. Patent for Cancer Drug
Immuneering rises on U.S. patent grant for atebimetinib
Immuneering (IMRX) Secures Patent for Cancer Drug Atebimetinib | IMRX Stock News
Immuneering granted atebimetinib patent by USPTO
Insider Buying: Thomas Schall Acquires Additional Shares of Immuneering Corp (IMRX)